[CIS PIDD] [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency

[Soheil Chegini]

Hello,
 
The right answer to that question very much depends on the objective of vaccination. You and all who commented so far would be perfectly right, if you only aim to provide immunity (therapeutic intent). 
 
If you, however wish to use vaccination as a diagnostic tool to gain insight into her underlying immunodeficiency and assess her ability to produce specific anti-polysaccharide antibodies in addition to a prophylactic intent to induce immunity and reduce her frequency of pneumococcal infections, you will have to use pure polysaccharide antigens (Pneumovax) and conjugation with a potent protein immune stimulant (Prevnar) will obscure the diagnostic aspect of this intervention. 
 
Best wishes,
 
Soheil Chegini, M.D.
Exton Allergy & Asthma Associates
656 West Lincoln Hwy.
Exton, PA 19341
Phone: (610) 269-3066
Fax: (610) 269-8615



On Wednesday, December 4, 2013 5:19 PM, "Verbsky, James" <jverbsky at mcw.edu> wrote:
  
Stan



For our patients in rheumatology on immunosuppression it is recommend to receive the PCV13 then the PPSV23.  We are doing this on all of our patients



Best

James



James Verbsky MD/PhD
Associate Professor of Pediatrics and Microbiology and Molecular Genetics
Medical College of Wisconsin
Milwaukee, WI  53226

________________________________
From: Stan Ress [stan.ress at uct.ac.za]
Sent: Wednesday, December 04, 2013 3:04 PM
To: CIS-PIDD
Subject: [cis-pidd] pneumococcal vaccine strategy in adolescents & adults with immune deficiency

Hi all,

I have been referred a 15 year-old patient with extremely severe IgA deficiency, recurrent respiratory infections, & bronchiectasis on CT chest. Her baseline vaccine status revealed low IgG ELIZA antibodies against 4/5 antigens, including S. pneumonia & H. Influenza B. Our policy has been to vaccinate such patients with 23-valent pneumococcal polysaccharide vaccine. However, I saw a reference to ACIP recommendation that children & adults with immune compromising conditions or asplenia, should receive 13-valent conjugate vaccine 1st, followed 8 weeks later by unconjugated PPSV23.

Is this the general current practise?

Thanks.
--
Stanley Ress
Associate Professor of Medicine
Head: Division of Clinical Immunology
Department of Medicine
H47 Old Main Building-room 26
Groote Schuur Hospital and UCT
Observatory 7925
Cape Town
South Africa
TEL:INTERN. + 2721-4066201 or 4066197
FAX:   "    + 2721-(0)865173095
Cell: 0833115482
email: stan.ress at uct.ac.za<mailto:stan.ress at uct.ac.za>

________________________________
UNIVERSITY OF CAPE TOWN

This e-mail is subject to the UCT ICT policies and e-mail disclaimer published on our website at http://www.uct.ac.za/about/policies/emaildisclaimer/or obtainable from +27 21 650 9111. This e-mail is intended only for the person(s) to whom it is addressed. If the e-mail has reached you in error, please notify the author. If you are not the intended recipient of the e-mail you may not use, disclose, copy, redirect or print the content. If this e-mail is not related to the business of UCT it is sent by the sender in the sender's individual capacity.

---

The CIS-PIDD listserv is supported by:

[http://www.clinimmsoc.org/UserFiles/image/cis-pidd-list-logo_v1.jpg]
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org<https://cis.execinc.com/edibo/Signup> to join!

You are currently subscribed to cis-pidd as: jverbsky at mcw.edu<mailto:jverbsky at mcw.edu>.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824783.922c198296ffdc754aad9421f3d685e1&n=T&l=cis-pidd&o=44201035

---
The CIS-PIDD listserv is supported by the Clinical Immunology Society
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org to join!

You are currently subscribed to cis-pidd as: schegini at yahoo.com.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183824417.b1e54082bbbf6f760251291ea6ac37ed&n=T&l=cis-pidd&o=44201286
or send a blank email to leave-44201286-183824417.b1e54082bbbf6f760251291ea6ac37ed at lists.clinimmsoc.org
---
The CIS-PIDD listserv is supported by the Clinical Immunology Society
The science & practice of human immunology

P: +1.414.224.8095
E: info at clinimmsoc.org

Not a member of CIS? Please visit www.clinimmsoc.org to join!

You are currently subscribed to cis-pidd as: pagid at list.clinimmsoc.org.
To unsubscribe click here: http://lm.clinimmsoc.org/u?id=183939985.3ea13d40a15475ac00ebbd9cd8a37d6d&n=T&l=cis-pidd&o=44201402
or send a blank email to leave-44201402-183939985.3ea13d40a15475ac00ebbd9cd8a37d6d at lists.clinimmsoc.org
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://seven.pairlist.net/pipermail/pagid/attachments/20131204/f7c12fe7/attachment.htm>